Free Trial
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Price, News & Analysis

TransMedics Group logo
$117.63 +1.95 (+1.69%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$117.28 -0.35 (-0.30%)
As of 10/17/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TransMedics Group Stock (NASDAQ:TMDX)

Advanced

Key Stats

Today's Range
$112.84
$118.30
50-Day Range
$104.01
$132.04
52-Week Range
$55.00
$145.50
Volume
671,084 shs
Average Volume
817,567 shs
Market Capitalization
$4.01 billion
P/E Ratio
60.95
Dividend Yield
N/A
Price Target
$127.18
Consensus Rating
Moderate Buy

Company Overview

TransMedics Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

TMDX MarketRank™: 

TransMedics Group scored higher than 65% of companies evaluated by MarketBeat, and ranked 327th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for TransMedics Group is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    TransMedics Group has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about TransMedics Group's stock forecast and price target.
  • Earnings Growth

    Earnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TransMedics Group is 60.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 200.35.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TransMedics Group is 60.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.78.

  • Price to Book Value per Share Ratio

    TransMedics Group has a P/B Ratio of 17.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about TransMedics Group's valuation and earnings.
  • Percentage of Shares Shorted

    23.88% of the outstanding shares of TransMedics Group have been sold short.
  • Short Interest Ratio / Days to Cover

    TransMedics Group has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in TransMedics Group has recently decreased by 2.98%, indicating that investor sentiment is improving.
  • Dividend Yield

    TransMedics Group does not currently pay a dividend.

  • Dividend Growth

    TransMedics Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.88% of the outstanding shares of TransMedics Group have been sold short.
  • Short Interest Ratio / Days to Cover

    TransMedics Group has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in TransMedics Group has recently decreased by 2.98%, indicating that investor sentiment is improving.
  • News Sentiment

    TransMedics Group has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for TransMedics Group this week, compared to 11 articles on an average week.
  • Search Interest

    36 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TransMedics Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of TransMedics Group is held by insiders.

  • Percentage Held by Institutions

    99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about TransMedics Group's insider trading history.
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TMDX Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
4 Analysts Have This To Say About TransMedics Group
See More Headlines

TMDX Stock Analysis - Frequently Asked Questions

TransMedics Group's stock was trading at $62.35 at the start of the year. Since then, TMDX stock has increased by 88.7% and is now trading at $117.63.

TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings results on Wednesday, July, 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group's revenue for the quarter was up 37.7% compared to the same quarter last year.
Read the conference call transcript
.

TransMedics Group (TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group's top institutional investors include Zevenbergen Capital Investments LLC (0.76%), Perigon Wealth Management LLC (0.06%), Yousif Capital Management LLC (0.03%) and Voya Investment Management LLC (0.03%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, Anil P Ranganath, David Weill, Edward M Basile, Stephanie Lovell and Laura Damme.
View institutional ownership trends
.

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
7/30/2025
Today
10/19/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TMDX
CIK
1756262
Fax
N/A
Employees
210
Year Founded
1998

Price Target and Rating

High Price Target
$155.00
Low Price Target
$75.00
Potential Upside/Downside
+8.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.93
Trailing P/E Ratio
60.95
Forward P/E Ratio
117.63
P/E Growth
N/A
Net Income
$35.46 million
Net Margins
13.49%
Pretax Margin
13.95%
Return on Equity
28.02%
Return on Assets
8.64%

Debt

Debt-to-Equity Ratio
1.61
Current Ratio
9.86
Quick Ratio
9.17

Sales & Book Value

Annual Sales
$531.29 million
Price / Sales
7.55
Cash Flow
$1.65 per share
Price / Cash Flow
71.49
Book Value
$6.81 per share
Price / Book
17.27

Miscellaneous

Outstanding Shares
34,090,000
Free Float
31,704,000
Market Cap
$4.01 billion
Optionable
Optionable
Beta
2.08

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TMDX) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners